ArticleCNS drugs2026

Ofatumumab Versus Intravenous Ocrelizumab after Sphingosine-1-Phosphate Receptor Modulators in Patients with Relapsing-Remitting Multiple Sclerosis: A Real-World Inverse Probability of Treatment Weighting Multicenter Study.

Gianmarco Abbadessa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.